Does XXXX induce @entity391 ?

@entity1 @entity391 @entity1286 @entity158 @entity282 @entity1209
OBJECTIVE: The aim of this prospective, controlled study was to evaluate the risk factors for @entity1209 in @entity1 undergoing gynecologic surgery and receiving @entity1 -controlled analgesia for three days. METHODS: Six hundred twenty-five gynecologic @entity1 with an American Society of Anesthesiologists physical status of I to III undergoing lower-abdominal surgeries were enrolled. A standard, general anesthetic technique was used. @entity282 was treated by a @entity1 -controlled analgesia device with bolus intravenous doses of 1 mg @entity1286 . For 3 days after surgery @entity1 were assessed for occurrence of @entity391 , sedation, and @entity158 intensity when at rest and during movement. RESULTS: The incidence of @entity391 was 26% on postoperative day 1, 13% on day 2, and 4% on day 3. On all 3 days, @entity1 ' @entity158 scores when at rest and when coughing were higher for those with @entity391 than for those without. During the first 2 postoperative days the @entity1 with and those without @entity391 consumed similar amounts of @entity1286 daily, but on the third day the @entity1 with @entity391 consumed significantly more @entity1286 than did those without @entity391 ( <0.05). Further logistic regression analysis showed that incident @entity158 was the main risk factor for @entity1209 on all 3 days. CONCLUSIONS: The results suggested that @entity282 was an associative risk factor to increase the incidence of @entity391 in these female @entity1 .
